Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Procainamide differs from quinidine in the following
respect(s):
A. It does not cause paradoxical tachycardia
B. It has no α adrenergic blocking activity
C. It has little antivagal action
D. Both ‘B’ and ‘C’ are corre
by

1 Answer

Answer :

D. Both ‘B’ and ‘C’ are correct
by

Related questions

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Procainamide differs from quinidine in the following respect (a) It does not cause paradoxical tachycardia (b) It has no alfa adrenergic blocking activity (c) It has little antivagal action (d) Both (b) and (c) Ans: D 68. In heart, potassium channels determine (a) Pacemaker function (b) Resting potential (c) Action potential duration (d) All of the above

Description : Procainamide differs from quinidine in the following respect (a) It does not cause paradoxical tachycardia (b) It has no alfa adrenergic blocking activity (c) It has little antivagal action (d) Both (b ... a) Pacemaker function (b) Resting potential (c) Action potential duration (d) All of the above

Last Answer : Ans: D

Quinidine can cause paradoxical tachycardia in a patient of: A. Sick sinus syndrome B. Atrial extrasystoles C. Atrial fibrillation D. Ventricular extrasystoles

Description : Quinidine can cause paradoxical tachycardia in a patient of: A. Sick sinus syndrome B. Atrial extrasystoles C. Atrial fibrillation D. Ventricular extrasystoles

Last Answer : C. Atrial fibrillation

Quinidine can cause paradoxical tachycardia in a patient of (a) Stick sinus syndrome (b) Auricular extrasystoles (c) Auricular fibrillation (d) Ventricular extrasystoles

Description : Quinidine can cause paradoxical tachycardia in a patient of (a) Stick sinus syndrome (b) Auricular extrasystoles (c) Auricular fibrillation (d) Ventricular extrasystoles

Last Answer : Ans: C

Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Description : Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Last Answer : D. Pimozide

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Description : The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Last Answer : C. Codergocrine

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

The following antiarrhythmic drug has the most prominent anticholinergic action: A. Disopyramide B. Quinidine C. Procainamide D. Lignocaine

Description : The following antiarrhythmic drug has the most prominent anticholinergic action: A. Disopyramide B. Quinidine C. Procainamide D. Lignocaine

Last Answer : A. Disopyramide

The following is true of procainamide except: A. It generates an active metabolite in the body B. Its plasma half-life is longer than that of quinidine C. On long-term use, it can cause systemic lupus erythematosus like illness D. It is effective in many cases of ventricular extrasystoles, not responding to lignocaine

Description : The following is true of procainamide except: A. It generates an active metabolite in the body B. Its plasma half-life is longer than that of quinidine C. On long-term use, it ... erythematosus like illness D. It is effective in many cases of ventricular extrasystoles, not responding to lignocaine

Last Answer : A. Disopyramide

Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Last Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Morphine induced constipation involves the following mechanisms except: A. Increase in tone and decrease in propulsive activity of intestinal muscles B. Antivagal action C. Spasm of gastrointestinal sphincters D. Reduction of gastrointestinal secretions

Description : Morphine induced constipation involves the following mechanisms except: A. Increase in tone and decrease in propulsive activity of intestinal muscles B. Antivagal action C. Spasm of gastrointestinal sphincters D. Reduction of gastrointestinal secretions

Last Answer : B. Antivagal action

The following adverse effect can occur even long after withdrawal of the offending drug: A. Paradoxical tachycardia B. Tardive dyskinesia C. Malignant hyperthermia D. Gynaecomastia

Description : The following adverse effect can occur even long after withdrawal of the offending drug: A. Paradoxical tachycardia B. Tardive dyskinesia C. Malignant hyperthermia D. Gynaecomastia

Last Answer : B. Tardive dyskinesia

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a adrenergic activity b. The renal and mesenteric vasoconstrictive effects of norepinephrine complicate and sometimes restrict its use c. The apparent paradoxical use of vasodilators, such as nitroprusside, in shock is indicated as a means to augment cardiac function d. Isoproterenol with its potent b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Description : Which of the following statement(s) is/are true concerning pharmacologic agents used in the treatment of shock? a. The primary difference between dopamine and dobutamine is the absence of significant a ... b-adrenergic effect, is a particularly useful agent in the treatment of all forms of shock

Last Answer : Answer: a, b, c Therapeutic adjustments of intravascular volume (preload) and systemic vascular resistance (afterload) form the basis of the treatment strategies for all ... careful constant monitoring of arterial pressure and repeated hemodynamic measurements with a pulmonary artery catheter

The following drug is preferred for termination as well as prophylaxis of paroxysmal supraventricular tachycardia: A. Digoxin B. Verapamil C. Propranolol D. Quinidine

Description : The following drug is preferred for termination as well as prophylaxis of paroxysmal supraventricular tachycardia: A. Digoxin B. Verapamil C. Propranolol D. Quinidine

Last Answer : B. Verapami

Quinidine is now used primarily for: A. Conversion of atrial fibrillation to sinus rhythm B. Control of ventricular rate in atrial flutter C. Termination of ventricular tachycardia D. Prevention of recurrences of atrial fibrillation/ ventricular tachycardia

Description : Quinidine is now used primarily for: A. Conversion of atrial fibrillation to sinus rhythm B. Control of ventricular rate in atrial flutter C. Termination of ventricular tachycardia D. Prevention of recurrences of atrial fibrillation/ ventricular tachycardia

Last Answer : D. Prevention of recurrences of atrial fibrillation/ ventricular tachycardia

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Description : 6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Last Answer : A. Dopamine D2 agonism

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Description : ndapamide differs from other diuretics in that: A. It has selective antihypertensive action at doses which cause little diuresis B. It is a more efficacious antihypertensive C. Its antihypertensive action develops more rapidly D. All of the above

Last Answer : A. It has selective antihypertensive action at doses which cause little diuresis

The limitations of quinidine in the treatment of cardiac arrhythmias include the following except: A. It has narrow spectrum antiarrhythmic activity B. It is not tolerated by many patients C. It can precipitate myocardial decompensation D. It can cause marked hypotension

Description : The limitations of quinidine in the treatment of cardiac arrhythmias include the following except: A. It has narrow spectrum antiarrhythmic activity B. It is not tolerated by many patients C. It can precipitate myocardial decompensation D. It can cause marked hypotension

Last Answer : A. It has narrow spectrum antiarrhythmic activity

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The 'new formula' WHO-ORS differs from the older 'standard formula' WHO-ORS in the following respect(s): A. It has lower Na+ ion and glucose concentration B. It has higher K+ ion concentration C. It has no basic salt D. Both 'B' and 'C' are correct

Description : The 'new formula' WHO-ORS differs from the older 'standard formula' WHO-ORS in the following respect(s): A. It has lower Na+ ion and glucose concentration B. It has higher K+ ion concentration C. It has no basic salt D. Both 'B' and 'C' are correct

Last Answer : A. It has lower Na+ ion and glucose concentration

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

What is true of risperidone: A. It is an atypical neuroleptic which produces few extrapyramidal side effects B. It has combined dopamine D2 and 5-HT2 receptor blocking activity C. It does not cause hyperprolactinemia D. Both 'A' and 'B' are correct

Description : What is true of risperidone: A. It is an atypical neuroleptic which produces few extrapyramidal side effects B. It has combined dopamine D2 and 5-HT2 receptor blocking activity C. It does not cause hyperprolactinemia D. Both 'A' and 'B' are correct

Last Answer : D. Both 'A' and 'B' are correct

A patient receiving a class I antiarrhythmic agent on a chronic basis complains of fatigue, low-grade fever, and joint pain suggestive of systemic lupus erythematosus (SLE). The patient is most likely receiving (a) Lidocaine (b) Procainamide (c) Quinidine (d) Flecainide (e) Propranolol

Description : A patient receiving a class I antiarrhythmic agent on a chronic basis complains of fatigue, low-grade fever, and joint pain suggestive of systemic lupus erythematosus (SLE). The patient is most likely receiving (a) Lidocaine (b) Procainamide (c) Quinidine (d) Flecainide (e) Propranolol

Last Answer : Ans: B

Strong anticholinergic effects limit the antiarrhythmic use of (a) Quinidine (b) Procainamide (c) Tocainide (d) Flecainide (e) Disopyramide

Description : Strong anticholinergic effects limit the antiarrhythmic use of (a) Quinidine (b) Procainamide (c) Tocainide (d) Flecainide (e) Disopyramide

Last Answer : Ans: E

Which of the following drugs depresses automaticity of SA node as well as ectopic foci, abbreviates action potential duration of Purkinje fibres, and slows atrioventricular conduction: A. Propranolol B. Lignocaine C. Procainamide D. Bretylium

Description : Which of the following drugs depresses automaticity of SA node as well as ectopic foci, abbreviates action potential duration of Purkinje fibres, and slows atrioventricular conduction: A. Propranolol B. Lignocaine C. Procainamide D. Bretylium

Last Answer : A. Propranolol

Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Description : Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Last Answer : A. Very long duration of action

e primary mechanism by which general anaesthetics produce their action is: A. Affecting receptor operated ion channels in cerebral neurones B. Blocking voltage sensitive Na+ channels in neuronal membrane C. Depressing metabolic activity of cerebral neurones D. Blocking production of high energy phosphates in the brain

Description : e primary mechanism by which general anaesthetics produce their action is: A. Affecting receptor operated ion channels in cerebral neurones B. Blocking voltage sensitive Na+ channels in neuronal ... activity of cerebral neurones D. Blocking production of high energy phosphates in the brain

Last Answer : A. Affecting receptor operated ion channels in cerebral neurones

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs are given in the initial intensive phase B. Duration of intensive phase is increased to 5 months C. Three drugs (HRE) are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Description : As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs ... are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Last Answer : D. Both 'A' and 'C'

Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Description : Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Last Answer : D. Both ‘A’ and ‘B’ are correct

Morphine analgesia differs from that produced by aspirin in the following respect(s): A. It has a higher ceiling B. It covers both perception as well as psychic processing of the pain C. Visceral and ischaemic pain is relieved better than somatic inflammatory pain D. All of the above are correct

Description : Morphine analgesia differs from that produced by aspirin in the following respect(s): A. It has a higher ceiling B. It covers both perception as well as psychic processing of the pain C. Visceral and ischaemic pain is relieved better than somatic inflammatory pain D. All of the above are correct

Last Answer : D. All of the above are correct

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Zolpidem differs from diazepam in that: A. It is safer in overdose than diazepam B. Its hypnotic action shows little fading on repeated nightly use C. It causes more marked suppression of REM sleep D. It has more potent muscle relaxant action

Description : Zolpidem differs from diazepam in that: A. It is safer in overdose than diazepam B. Its hypnotic action shows little fading on repeated nightly use C. It causes more marked suppression of REM sleep D. It has more potent muscle relaxant action

Last Answer : B. Its hypnotic action shows little fading on repeated nightly use

The action of quinidine differs from that of digitalis in (a) Decreasing irritability of cardiac muscle (b) Preventing passage of impulses to the ventricle (c) Increasing irritability of heart muscle (d) Reducing conductivity (e) None of the above

Description : The action of quinidine differs from that of digitalis in (a) Decreasing irritability of cardiac muscle (b) Preventing passage of impulses to the ventricle (c) Increasing irritability of heart muscle (d) Reducing conductivity (e) None of the above

Last Answer : Ans: A

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release